

**Supplementary Table 2.** Cost inputs and utility inputs

Variable	Value (KRW)	References
<b>Cost input</b>		
Drug cost (yearly) (original)		Korean National Health Insurance Service [30]
Denosumab	355,300	
Alendronate	276,442	
Ibandronate (IV)	206,220	
Ibandronate (oral)	231,552	
Zoledronate	214,592	
Risedronate	218,088	
Raloxifene	257,136	
Drug cost (yearly) (weighted average cost)		Korean National Health Insurance Service [31]
Denosumab	355,300	
Alendronate	277,955	
Ibandronate (IV)	214,964	
Ibandronate (oral)	229,752	
Zoledronate	214,592	
Risedronate	204,108	
Raloxifene	257,501	
Direct cost of clinical event (per year) (considering copayment rate)		Health Insurance Review & Assessment Service [27]
Vertebral fracture	4,651,492	
Wrist fracture	5,538,351	
Hip fracture	15,363,707	
Other fracture	6,327,605	
Other unit cost		Health Insurance Review & Assessment Service [28]
Daily cost of nursing home/long-term care	7,136	
Cost of BMD measurement	35,604	
Cost of physician visit	8,411	
Cost of IV per injection	1,622	
Cost of a pharmacy visit	5,142	
<b>Utility input</b>		
Utility of normal population (age)		The 2014 Korea National Health and Nutrition Examination Survey
50	0.94	
55	0.93	
60	0.91	
65	0.88	
70	0.85	
75	0.79	
80	0.75	
85	0.82	
90	0.90	
Utility multipliers (fracture type/period)		Bae and Kwon [16]
First year after fracture		
Hip fracture 1st year	0.700	
Vertebral fracture 1st year	0.590	
Wrist fracture	0.956	
Other fracture	0.902	
Second and following years after fracture		
Hip fracture 2nd and following years	0.800	
Vertebral fracture 2nd and following years	0.929	

BMD, bone mineral density.